No OS benefit was shown with atezolizumab over docetaxel in NSCLC patients with EGFR mutations (HR = 1.24 95% CI:0.71–2.18) vs. WT (HR = 0.69, 95% CI:0.57–0.83). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.